Benefits and Risks of Manipulating the HIF Hydroxylase Pathway in Ischemic Heart Disease
Ischemic heart disease is a major cause of morbidity and mortality in the Western world. It occurs when oxygen delivery cannot meet the metabolic needs of the heart, as observed in patients with stable coronary artery disease as well as those experiencing acute myocardial infarction. Although conditions leading to myocardial injury have been well studied, and physical means of revascularization by stenting or coronary bypass surgery are well developed, there remains a need to define treatments that limit damage in the acute phase or promote revascularization by medical means. In particular, mechanisms that preserve cellular function during ischemia remain poorly understood.
KeywordsIschemic Insult Stable Coronary Artery Disease Prolyl Hydroxylase Domain Minimize Tissue Damage Intraventricular Infusion
- 17.Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler 3rd AA. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol. 2007;293:H1571–80.PubMedCrossRefGoogle Scholar
- 21.Adluri RS, Thirunavukkarasu M, Dunna NR, et al. Disruption of HIF-prolyl hydroxylase-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through HIF-1alpha transcription factor and its target genes in mice. Antiox Redox Signal 2011;15:1789–97.Google Scholar